Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Aeglea BioTherapeutics, Inc. | agle-ex321_11.htm |
| EX-31.1 - EX-31.1 - Aeglea BioTherapeutics, Inc. | agle-ex311_9.htm |
| EX-21.1 - EX-21.1 - Aeglea BioTherapeutics, Inc. | agle-ex211_12.htm |
| EX-4.5 - EX-4.5 - Aeglea BioTherapeutics, Inc. | agle-ex45_723.htm |
| EX-4.3 - EX-4.3 - Aeglea BioTherapeutics, Inc. | agle-ex43_722.htm |
| 10-K - 10-K - Aeglea BioTherapeutics, Inc. | agle-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-239706 and 333-228967) and Form S-8 (No. 333-210633, 333-216903, 333-223614, 333-230137 and 333-236584) of Aeglea BioTherapeutics, Inc. of our report dated March 18, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Austin, Texas
March 18, 2021